Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.31 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263983 | 0.87 | TAS1R3 (0.36) | TAS1R3TAS1R1P2RX3P2RX2TYMP | |
| SCHEMBL22349173 | 0.84 | TYMP (0.33) | TYMPSLC29A1 | |
| SCHEMBL20692127 | 0.84 | TYMP (0.33) | TYMPSLC29A1 | |
| SCHEMBL20691327 | 0.79 | SLC29A1 (0.31) | SLC29A1 | |
| SCHEMBL20692221 | 0.79 | P2RX3 (0.36) | P2RX3TYMPADORA1RNASEL | |
| SCHEMBL20691938 | 0.78 | HIF1A (0.33) | TYMPSLC29A1 | |
| SCHEMBL22349203 | 0.76 | STING1 (0.38) | P2RX3TYMP | |
| SCHEMBL20691457 | 0.76 | DNPH1 (0.32) | SLC29A1 | |
| SCHEMBL20691298 | 0.76 | AHCY (0.37) | TYMPRNASEL | |
| SCHEMBL20691336 | 0.73 | RNASEL (0.42) | P2RX3P2RX2RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | TAS1R3 4686/4885TAS1R1 4753/4885P2RX3 1547/4885 |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | TAS1R3 4686/4885TAS1R1 4753/4885P2RX3 1547/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | TAS1R3 4686/4885TAS1R1 4753/4885P2RX3 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.